Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Veradermics, IncMANE · Entity 1907 | Director | February 03, 2026 | February 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Veradermics, Inc
Report date February 03, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,455 |
Reported balance
After 2026-02-05 transaction · row 1
1 source rowRow 1 · 2026-02-05 · Conversion · Acquired 2,455 · Balance 2,455 F1: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share, on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-02-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-05 · Conversion · Disposed 2,455 · Balance 0 F1: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share, on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-02-03 | Direct | 51,525 |
Reported balance
After 2026-02-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-03 · Grant · Acquired 51,525 · Balance 51,525 F2: This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share, on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
F2: This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2026 Filed Feb 6, 2026 00:05 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionSeries A Convertible Preferred Stock · Derivative | 2,455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005910 · wk-form4_1770336315.xml · derivative · entry 2 Grant-Kels Jane M. · CIK 0002108622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,455 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share, on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share, on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share, on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share, on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:05 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionCommon Stock | 2,455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005910 · wk-form4_1770336315.xml · nonDerivative · entry 1 Grant-Kels Jane M. · CIK 0002108622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share, on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share, on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 00:05 UTC | Veradermics, Inc MANE · Entity 1907 | GrantStock Option (Right to Buy) · Derivative | 51,525 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001628280-26-005910 · wk-form4_1770336315.xml · derivative · entry 3 Grant-Kels Jane M. · CIK 0002108622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,525 Underlying: Common Stock · 51,525 shares Expires 2036-02-03 F2 · derivative.exercise_date: This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.